INMUNE BIO INC. - COMMON STOCK

INmune Bio Announces Results of Additional Blinded Interim Analysis of Phase 2 Alzheimer's Disease Trial Demonstrating Correlation between EMACC and CDR-SB Endpoints

17 Sep 2024 07:30:00 By Nasdaq GlobeNewswire

INmune Bio Announces $13.0 Million Registered Direct Offering

13 Sep 2024 07:30:00 By Nasdaq GlobeNewswire

INmune Bio Inc. to Present at the Baird 2024 Global Healthcare Conference

03 Sep 2024 08:00:00 By Nasdaq GlobeNewswire

INmune Bio Inc. Announces Second Quarter 2024 Results and Provides Business Update

01 Aug 2024 15:05:39 By Nasdaq GlobeNewswire

INmune Bio Inc. Announces New Phase 1 Study Data Demonstrating Dose-Dependent Effect of XPro™ on Proteins that Regulation Synapses in Alzheimer’s Patients

29 Jul 2024 08:00:00 By Nasdaq GlobeNewswire

INmune Bio Inc. to Report Second Quarter 2024 Financial Results and Provide a Corporate Update on Thursday, August 1, 2024

25 Jul 2024 07:00:00 By Nasdaq GlobeNewswire

INmune Bio Inc. Publishes Novel Biology on Natural Killer Cancer Immunotherapy INKmune™ in the Journal for ImmunoTherapy of Cancer

23 Jul 2024 07:45:00 By Nasdaq GlobeNewswire

INmune Bio, Inc. Completes Blinded Interim Analysis of Phase II Alzheimer’s Disease Trial

27 Jun 2024 07:00:00 By Nasdaq GlobeNewswire

INmune Bio Inc. to Join Russell 3000® Index

30 May 2024 07:00:00 By Nasdaq GlobeNewswire

INmune Bio Inc. Announces First Quarter 2024 Results and Provides Business Update

09 May 2024 15:05:36 By Nasdaq GlobeNewswire

INmune Bio Inc. to Report First Quarter 2024 Financial Results and Provide a Corporate Update on Thursday, May 9

07 May 2024 07:00:01 By Nasdaq GlobeNewswire

INmune Bio Inc. Provides Update on Two Patients from the Phase 1b Alzheimer’s Disease Trial who Continue to Receive XPro™ Under Compassionate Use for Over Three Years

30 Apr 2024 07:00:00 By Nasdaq GlobeNewswire

INmune Bio Inc. Completes First Cohort and Initiates Second Cohort of Phase 1/2 Study of INKmune™ Natural Killer Cell Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer

29 Apr 2024 07:00:00 By Nasdaq GlobeNewswire

INmune Bio Inc. Announces $9.7 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

25 Apr 2024 08:00:00 By Nasdaq GlobeNewswire

INmune Bio Inc. Announces 24-Month Stability Validation of XPro™ for Phase III Readiness and Commercial Supply Chain Modeling & Development of Novel Immunogenicity Assay

23 Apr 2024 07:00:00 By Nasdaq GlobeNewswire

INmune Bio Inc. Raises Approximately $4.8 Million in Gross Proceeds Through Registered Direct Offering with Officers, Employees and Directors Purchasing Approximately 20% of the Offering

22 Apr 2024 07:00:00 By Nasdaq GlobeNewswire

INmune Bio Inc. Presents Data on INB03’s Role as an Immune Check Point Modulator in the Treatment of High-Risk Breast Cancer at AACR 2024

08 Apr 2024 07:00:01 By Nasdaq GlobeNewswire

INmune Bio Inc. Announces Year End 2023 Results and Provides a Q4 Business Update

28 Mar 2024 15:01:53 By Nasdaq GlobeNewswire

INmune Bio Inc. to Report Fourth Quarter 2023 Financial Results and Provide a Corporate Update on Thursday, March 28

26 Mar 2024 15:01:00 By Nasdaq GlobeNewswire

INmune Bio CSO and Co-Founder Mark Lowdell, Ph.D. Receives The ISCT Career Achievement Award in Cell and Gene Therapy

13 Mar 2024 07:00:00 By Nasdaq GlobeNewswire